Clinical Trial Update: CLL-1 CAR-NK Cells for Relapsed/Refractory AML [Phase 1]

View source ↗

Summary

This clinical trial update reports a Phase 1 study evaluating CAR-NK cells targeting CLL-1 for relapsed or refractory acute myeloid leukemia, which is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• CLL-1 CAR-NK cells (CAR-NK therapy targeting CLL-1 (CLEC12A))

Snippet

Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Conditions: Relapsed Adult AML, Refractory AML | Phase 1 | Status: RECRUITING